Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01651715
Other study ID # ESTUAR001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received July 25, 2012
Last updated August 5, 2013
Start date September 2012
Est. completion date August 2013

Study information

Verified date August 2013
Source Theranor s.p.r.l
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether early self-treatment with homeopathic dilutions of oral antibodies to a key-protein of the immune system are effective and safe in the treatment of viral upper respiratory tract infections


Description:

TAO1 is an investigational medicinal product containing homoeopathic dilutions (<10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.

The validity of the TAO1 development approach was addressed in a proof of concept study of efficacy in a non-lethal influenza infection in mice. In this blinded study, TAO1 was given in drinking water for 5 days before and 10 days after viral challenge. The statistical analysis of preclinical data was carried out by using the Mann-Whitney non-parametric test (2-tailed). The clinical disease duration was significantly reduced from 6.0 (5.25 (25th percentile);7.0 (75th percentile)) days to 5.0 (5.0;5.0) days (p=0.00037) as well as the overall disease severity that was lowered from 8.0 (7.0;10.0) points to 6.0 (5.0;7.5) points (p=0.00032).

Given the high homoeopathic dilution, the active substance in the finished product lies beyond sensitivity of existing analytical assays. TAO1 is therefore not amenable to pharmacokinetics studies.

There are currently no data on clinical efficacy of TAO1 in common cold obtained in double-blind placebo-controlled clinical trials. Based on the efficacy in the animal model, the expected magnitude of effect of TAO1 in humans is a reduction of common cold duration by 2-3 days, provided that the treatment is started early after the onset of the symptoms.

Primary objective:

To evaluate the efficacy of TAO1 in reducing the severity of symptoms of common cold in otherwise healthy adults.

Secondary objectives:

To evaluate the efficacy of TAO1 in reducing the duration of common cold. To evaluate the impact of TAO1 on health-related Quality of Life (functional impairment) in patients with common cold.

To evaluate the safety of TAO1.

Experimental design: Double-blind, parallel-group, randomised, multicentre, placebo-controlled study.

Treatment allocation: Balanced allocation between TAO1 and placebo (1:1).

At Visit 1, the medications, questionnaires and diary cards will be dispensed to patients who have signed informed consent. Upon contracting a common cold, they will start the treatment immediately and take contact with the doctor by phone within 36 hours. On Day 2-3 after the onset of disease, they will visit the doctor (Visit 2) to confirm the diagnosis. The doctor will check if questionnaires are filled in correctly. On the 10-14th day (at the latest) after start of treatment, Visit 3 is planned to pick up questionnaires, evaluate safety, disease complications and treatment compliance.

Treatment group: TAO1 tablets (to be dissolved in the mouth, not to be swallowed; should be taken at least 10 minutes apart from meals and/or smoking):

Day 1: 3 tablets to be taken over the first 2 hours of treatment, then 3 tablets over the rest of Day 1,

Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime),

Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).

Control: Placebo tablets: same dosage regimen as for TAO1.

Concomitant medications: Only oral analgesics/antipyretics, such as paracetamol or ibuprofen, will be allowed in case of fever or headache. Each intake of such medications will be registered in the patient's diary.

Severity and duration of self-reported symptoms evaluated daily by the validated Wisconsin Upper Respiratory Symptom Survey short version (WURSS-21)

Evaluation of safety: adverse events (AEs) and serious adverse events (SAEs) coded using the Medical Dictionary for Regulatory Activities (MedDRA) assessed according to their frequency, severity, outcome and relationship to the study drug.

Data collection: Paper Case Report Form (CRF).

Duration of treatment: 7 days

Duration of study: maximum 10 months.

Number of Investigators: about 35 investigators (General Practitioners).

Type of study: Phase II, self-contained study

Number of patients: 240 (120 treated with TAO1 and 120 treated with placebo)

Sample size justification: A sample size of 115 in each group will have 80% power to detect a difference in mean AUCs of 103 (a difference of 30% between a Placebo AUC mean of 310 and a TAO1 AUC mean of 207) assuming that the common standard deviation is 277 using a two group t-test with a 0.050 two-sided significance level.


Recruitment information / eligibility

Status Completed
Enrollment 232
Est. completion date August 2013
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Outpatients aged > or = 18 years

- Ability and willingness to adhere to the study protocol

- Signed informed consent

- Self-reported recently emerged symptoms of common cold: answer "Yes" to the question "Do you believe that you are coming down with a cold?"

- At least one of the following 4 common cold symptoms: sneezing, runny nose, nasal obstruction and/or sore throat, with no limitations of symptom severity.

Exclusion Criteria:

- Specific chronic diseases (autoimmune disease, chronic bronchitis, human immunodeficiency virus (HIV) infection, lupus, rheumatoid arthritis)

- Malignancy for which the patient has undergone resection, radiation or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.

- Cancer therapy

- Immunosuppressant therapies

- Use of systemic corticosteroids

- A history of asthma or allergic rhinitis and corresponding symptoms (itchy eyes, sneezing, wheezing)

- Any of the common cold symptoms persisting since more than 36 hours

- Use of other homeopathic drugs designed to treat URTIs

- Use of antibiotics, anti-histaminergic drugs or decongestants

- Participation in another clinical trial within one month prior to treatment start

- Previous participation (receipt of randomised treatment) in this study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
TAO1, oral homeopathic antibodies
TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets). The investigational product will be taken for 7 days as follow: Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1. Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).

Locations

Country Name City State
Belgium Jean-Pierre Devaux Baisy-Thy Brabant
Belgium Etienne Plees Beringen Limburg
Belgium Patrice Lechien Braine-le-Comte Hainaut
Belgium Virginie Risse Bruxelles Brabant
Belgium Frank Heyvaert Deurne Antwerpen
Belgium Charles Corbisier Ecaussinnes Hainaut
Belgium Christel Van Der Geer Geel Antwerpen
Belgium Hugo Loos Geel Antwerpen
Belgium Elise De Meulemeester Gozée Hainaut
Belgium Magali Trefois Gozée Hainaut
Belgium Yvan Calozet Gribomont Luxembourg
Belgium Nicole Olaerts Ham Limburg
Belgium Aubry Robert Ham-sur-Heure Nalinnes Hainaut
Belgium Philippe Jacques Ham-sur-Heure Nalinnes Hainaut
Belgium Guy Van Damme Heusden Oost Vlaanderen
Belgium Roel De Ryck Kraainem Brabant
Belgium Paul Beke Leopoldsburg Limburg
Belgium Pierre-Henri Arnould Libramont-Chevigny Luxembourg
Belgium ResearchLink sprl Linkebeek Brabant
Belgium Stéphane Vanden Bemden Melsbroek Brabant
Belgium Jan Joris Mol Antwerpen
Belgium Steven Windmolders Overpelt Limburg
Belgium Jan Behets Paal Limburg
Belgium Jos Weckx Paal Limburg
Belgium Michel Grégoire Pont-à-Celles Hainaut
Belgium Bart Van Essche Steenokkerzeel Brabant
Belgium Herman Van Den Broeck Tessenderlo Limburg
Belgium Etienne Demanet Thuin Hainaut
Belgium Maria Buscemi Thuin Hainaut
Belgium Erik Schreurs Tremelo Brabant
Belgium Lode Vermeersch Tremelo Brabant
Belgium Luc De Munck Vilvoorde Brabant
Belgium Jan De Jongh Vorst Antwerpen

Sponsors (1)

Lead Sponsor Collaborator
Theranor s.p.r.l

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severity of symptoms of common cold Decrease in severity is assessed as reduction in average area under the curve (AUC) under the time severity curve (sum of all WURSS scores over the follow-up). The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) is a validated tool to evaluate the duration and severity of common cold. It is constituted of twenty-one categorical questions (Likert-type 7-level severity scale). Since start of symptoms of common cold up to the visit 3 (day 10-14) No
Secondary Duration of common cold Duration is defined as the number of days from self-reported onset of disease to the last day before the participant answered "Not sick" to the question, "How sick do you feel today?" (WURSS-21). A 2-day reduction in average disease duration versus placebo will be regarded as clinically significant. Since start of symptoms of common cold up to visit 3 (Day 10-14) No
Secondary Functional impairments in the course of the disease Day-to-day scores for functional impairments domain. Overall (sum of all WURSS scores related to functional impairments over the follow-up). Since start of symptoms of common cold up to visit 3 (Day 10-14) No
Secondary The need of symptomatic analgesics/antipyretics Patients will fill in diary cards on a daily basis. The following information will be recorded: study and patient identification, date of assessment, study medication intake, other medications (name, dose, frequency) and, AEs/SAEs (description) Since start of symptoms of common cold up to visit 3 (Day 10-14) Yes
Secondary Evaluation of safety Patients will fill in diary cards on a daily basis including AEs/SAEs reporting. Investigators will question patients at phone call and scheduled visits about AEs/SAEs. Frequency, severity, outcome and relationship to the study drug will be assessed. since start of symptoms of common cold up to visit 3 (Day 10-14) Yes
See also
  Status Clinical Trial Phase
Completed NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections Phase 3
Completed NCT02451163 - DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly Phase 2
Completed NCT01944631 - Iota-Carrageenan Nasal Spray in Common Cold Phase 4
Completed NCT00963443 - Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold Phase 3
Completed NCT00778648 - Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms N/A
Completed NCT00065715 - Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo) Phase 3
Completed NCT00032500 - Evaluation of Echinacea for the Common Cold Phase 2
Not yet recruiting NCT05070650 - Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold Phase 3
Not yet recruiting NCT04073511 - Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold N/A
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Terminated NCT01964885 - Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections Phase 3
Completed NCT01277081 - Effect of Paracetamol on the Common Cold Phase 2
Completed NCT01728090 - Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections Phase 4
Completed NCT00405509 - The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years N/A
Completed NCT01033526 - Symptomatic Treatment of Common Cold Symptoms Phase 4
Completed NCT05556148 - Otrivine: Quality of Life (QoL) Impact in a Real-World Setting Phase 4
Terminated NCT03339726 - Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold Phase 2
Completed NCT01361399 - Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold Phase 3
Recruiting NCT05244148 - Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects N/A